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Abstract
Follicular thyroid carcinoma (FTC) tends to metastasize to remote organs rather than local lymph nodes. Separation
of FTC from follicular thyroid adenoma (FTA) relies on detection of vascular and/or capsular invasion. We investi-
gated which vascular markers, CD31, CD34 and D2-40 (lymphatic vessel marker), can best evaluate vascular inva-
sion and why FTC tends to metastasize via blood stream to remote organs. Thirty two FTCs and 34 FTAs were
retrieved for evaluation. The average age of patients with FTA was 8 years younger than FTC (p = 0.02). The female
to male ratio for follicular neoplasm was 25:8. The average size of FTC was larger than FTA (p = 0.003). Fourteen of
32 (44%) FTCs showed venous invasion and none showed lymphatic invasion, with positive CD31 and CD34 stain-
ing and negative D2-40 staining of the involved vessels. The average number of involved vessels was 0.88 ± 1.29
with a range from 0 to 5, and the average diameter of involved vessels was 0.068 ± 0.027 mm. None of the 34
FTAs showed vascular invasion. CD31 staining demonstrated more specific staining of vascular endothelial cells
than CD34, with less background staining. We recommended using CD31 rather than CD34 and/or D2-40 in con-
firming/excluding vascular invasion in difficult cases. All identified FTCs with vascular invasions showed involve-
ment of venous channels, rather than lymphatic spaces, suggesting that FTCs prefer to metastasize via veins to
distant organs, instead of lymphatic vessels to local lymph nodes, which correlates with previous clinical
observations.
Introduction
Follicular thyroid carcinoma (FTC) accounts for 10 -
17% of clinically evident thyroid malignancies [1-4]. It is
more common in women, and tends to occur in patients
in the fifth decade[1]. Survival is better in women and in
patients younger than 40 years for male and 50 years for
female [4-6]. Separation of FTC from follicular thyroid
adenoma (FTA) is based on detection of vascular and/or
capsular invasion[1]. The vascular invasion is almost
never evident grossly[7]. Microscopically, the vessels
should be located in or immediately outside the capsule
(rather than within the tumor), and contain one or
more clusters of tumor cells attached to the wall with
protrusion into the lumen[1,7]. Often, the intravascular
tumor foci are covered by endothelium, in a fashion
similar to that of an ordinary thrombus[7]. The
endothelial markers, such as CD31, factor VIII-related
antigen, and Ulex europaeus, have been used in identify-
ing vascular invasion [8-10]. When vascular invasion is
identified in FTCs, there is a prognostic significance
based on the number of vessels involved (< 4 or ≥ 4 vas-
cular invasion)[7,11-15].
Clinically, FTC tends to spread via blood stream, espe-
cially to the bones and lungs, and rarely to regional
lymph nodes[1,16-20]. The skeletal metastases are
usually multicentric but have a predilection for the
shoulder girdle, sternum, skull, and iliac bone[21,22].
These metastases are common in the FTCs demonstrat-
ing extensive vascular invasion, but occur in fewer than
5% FTCs with minimal vascular invasion, and develop in
less than 1% of the tumors diagnosed as carcinoma only
on the basis of minimal capsular invasion[14,23,24].
Thirteen percentage of FTC smaller than 3 cm, 19%
FTC between 3 to 6 cm, and 33% FTC > 6 cm show
vascular invasion[25]. Up to 10 % of patients with folli-
cular or Hurthle cell carcinoma have tumors that
aggressively invade structures in the neck or produce
distant metastasis[26]. The metastases may exhibit a bet-
ter differentiated appearance than the primary tumor, to
the point of simulating normal thyroid as an expression
of terminal differentiation (so-called “metastasizing
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ter”) [ 7 ] .T h em a j o r i t y ,h o w e v e r ,h a v ep o o r l yd i f f e r e n -
tiated features, at least at the architectural level[20].
Occasionally, it can be challenging to detect vascular
invasion on hematoxylin and eosin (H&E) stained slides.
Although vascular immunohistochemical (IHC) markers
such as CD31[27,28], Factor VIII[9,10], Ulex europaeus
[8] and CD34[27,29] have been used to identify vascular
invasion in malignant neoplasms, the diagnostic value of
these vascular markers compared to a specific lymphatic
IHC marker, D2-40, in FTC has not been investigated
[30,31]. In this study we investigated which vascular
markers, CD31, CD34 and D2-40, can best identify vas-
cular invasion in FTC, and studied whether venous or
lymphatic vessels were involved. To date, no study has
demonstrated a predilection of FTC for invading venous
versus lymphatic vessels.
Materials and methods
Selection of Cases
The institutional review board of Allegheny General
Hospital, Pittsburgh, PA approved the study. Thirty four
follicular thyroid adenomas (FTA) and 32 follicular thyr-
oid carcinomas (FTC) from 2000 to 2008 were retrieved
from the hospital computer system. All FTCs were diag-
nosed when vascular and/or capsular invasion was histo-
logically present. All patients were followed-up from 1
to 8 years, and none of the patients showed distal
metastasis.
The average tumor size of FTA and FTC was 2.8 ± 0.9
cm with a range from 1.1 to 5.5 cm and 4.4 ± 2.0 with a
range from 1.4 to 7.5 cm, respectively (P = 0.003). The
average age of patients with FTA was approximately 8
years younger than those with FTC (48.2 ± 11.3 vs. 56.7
± 11.6 years old, P = 0.02). The average age for male
and female patients with FTC was 55.2 ± 9.75 and 56.2
± 13.0, respectively (P = 0.91). The female to male ratio
with follicular thyroid neoplasm was 25:8, suggesting
female predominance. The female to male ratios of FTA
and FTC were 15:2 and 5:3, respectively (p = 0.000007).
Pathologic evaluation and immunohistochemistry
Formalin-fixed (10 % buffered formalin), routinely pro-
cessed, hematoxylin and eosin-stained (H&E) tissue sec-
tions including the entire capsule of the tumor were
evaluated independently by 2 pathologists (XL and YL).
Two blocks with capsule vascular invasion identified on
H&E stained slides or suspicious for vascular invasion
from each case were chosen for immunohistochemical
study.
Paraffin-embedded blocks were sectioned, deparaffi-
nized, rehydrated, and blocked with methanolic 3%
hydrogen peroxide. Antigen retrieval was performed in
citrate buffer (pH 6.0). The immunohistochemical stains
(IHC) for CD31 (catalog number CMA338, clone jc70a,
Mouse IgG1, no dilution, Cell Marquee, Hot Springs,
AR), CD34 (catalog number 790-2927, clone QBEnd/10,
mouse IgG1, no dilution, Ventana, Tucson, AR), and
D2-40 (catalog number 730-01, clone D2-40, mouse
IgG1, 1:50 dilution, Signet, Dedham, MA) on these
slides were performed in an automated immunostainer
w i t ha p p r o p r i a t ep o s i t i v ea n dn e g a t i v ec o n t r o l s .T h e
detection was performed with Iview DAB detection kit
(Catalog number 760-091, Vantana, Tucson, AZ). All
slides were counterstained with hematoxylin and then
were evaluated independently by 2 pathologists (XL and
YL).
Statistics
The vascular invasion results from reviewing H&E and
IHC stained slides by two pathologists were compared.
Chi-square test and Student T test were used for statis-
tical analysis.
Results
Identification of vascular invasion of follicular thyroid
neoplasms
In this study, we identified vascular invasion in 13 FTC
cases and no FTA cases by H&E stained slides (Table 1
and Figure 1). IHC stain with CD31 and CD34 identified
one more case in the FTC group, but no additional case
i nt h eF T Ag r o u p .I nt h eF T Cg r o u p ,o n ec a s ew a s
reported as “vascular invasion is equivocal”, but capsular
invasion was present. Reexamination of the equivocal
case confirmed vascular invasion on repeat H&E slides,
which further was confirmed with IHC stains for CD31
and CD34. These results suggested that IHC stain with
CD31 and CD34 could help identify more vascular inva-
sion and identify vascular invasion more accurately, and
that IHC staining with CD31 or CD34 should be done
especially if vascular invasion was equivocal. We also
found that CD34 stained many non-endothelial cells,
which occasionally compromised evaluation of vascular
invasion. In contrast, CD31 was more specific than
CD34 for vascular endothelial cells, making evaluation
of vascular invasion much clearer.
The average number of vessels demonstrating vascular
invasion was 0.88 ± 1.29 with a range from 0 to 5. The
average diameter of involved vessels was 0.068 ± 0.027
mm.
The vessels invaded by FTC were venous rather than
lymphatic
Antibodies against CD31[27,28] and CD34[27,29] are
two widely-used markers of vascular endothelial cells
and stain endothelial cells of both blood and lymphatic
vessels, in contrast to D2-40 which stains only the
endothelial cells of lymphatic vessels[30,31]. In this
study, we found that all the vessels invaded by the FTCs
were stained with CD31 and CD34 and none were
stained with D2-40, supporting that venous rather than
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Neoplasms No. H&E D2-40 CD31 CD34
Follicular Carcinoma 32 41 % (13/32)* 0 % (0/32) 44 % (14/32)* 44 % (14/32)*
Follicular Adenoma 34 0 % (0/34) 0 % (0/34) 0 % (0/34) 0 % (0/34)
Figure 1 Follicular thyroid adenoma (A, C, E and G) and follicular thyroid carcinoma (B, D, F and H) (400×). Hematoxylin and eosin stains
(A and B), CD31 stains (C and D), CD34 stains (E and F), and D2-40 stains (G and H).
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1). These results indicated FTC prefers to invade the
venous rather than the lymphatic vessels.
Discussion
The diagnosis of FTC is contingent upon identifying
capsular and/or vascular invasion[1]. Identification of
the number of vessels involved by FTC is also important
to predict prognosis (< 4 or ≥ 4 vascular invasion)[7,11].
In this study, we found that antibody against CD31 is
better than antibodies against CD34 and D2-40 in iden-
tifying FTC vascular invasion and that FTC prefers to
invade the venous rather than the lymphatic vessels.
Occasionally, it can be difficult to identify vascular
invasion on H&E stained slides[1,7]. One of our cases
showed capsular invasion, but was initially equivocal for
vascular invasion. However, vascular invasion was con-
firmed with IHC stains for CD31 and CD34. In addition,
IHC stains for CD31 and CD34 identified vascular inva-
sion in one case that was missed in the H&E stained
slides. Therefore, any suspicion for vascular invasion
should be confirmed by IHC stains for CD31 and CD34,
since IHC stains for CD31 and CD34 can more accu-
rately and readily identify vascular invasion. We found
that CD31 is preferable to CD34 for detecting vascular
invasion of FTC due to less background staining. It is
important to identify the vascular invasion, as the degree
of vascular invasion by FTC has important prognostic
implications[7,11].
Clinically, FTC is observed to metastasize hematogen-
ously to distant organs in 7 - 40% of patients, with special
preference to the lung and bones, rather than via lympha-
tics to regional nodes[2,19,20,25,32-34]. To date, no
study has shown a preference of invading venous blood
vessels versus lymphatic vessels by FTC. Antibodies
against CD31 and CD34 stain both venous and lymphatic
endothelial cells [27-29]. However, an antibody against
D2-40 is a very sensitive and specific marker for lympha-
tic endothelial cells[30,31]. In this study, the endothelial
cells of the vascular invasions in FTC were positive CD31
and CD34 and negative for D2-40, strongly suggesting
that vascular invasion of FTC involves venous but not
lymphatic vessels, which correlates with previous clinical
observations[19,20]. However, the reason for this phe-
nomenon is unknown, since papillary carcinoma is
known to have a strong proclivity to involve lymphatic
vessels with regional lymph node metastasis. In this
study, we found that both D2-40 negative venous and
D2-40 positive lymphatic vessels are present in the FTC
and FTA capsules, excluding the possibility of lack of
lymphatic vessels in the capsules. Future study on the
preference of venous invasion by the FTC is important in
order to further clarify the clinical behavior of FTC and
to predict prognosis of FTC. In this study, no case
showed distal and local metastasis during 1 to 8 years fol-
low-up. Two cases with 4 or 5 venous vessels involved
respectively also did not show distant metastasis 6 years
after excision of FTC, but our observation may be limited
by the relatively short follow-up. Another reason that
may contribute to our finding is that with incoming use
of thyroid fine needle biopsy to evaluate thyroid nodule
in recent years, more FTC cases are potentially being
diagnosed and treated at an earlier stage.
It was reported that FTC is more common in women,
and tends to occur in patients in the fifth decade[1]. In
this study, we had similar findings that the female to
male ratio with follicular neoplasm was 25:8, with in
15:2 female to male ratio in FTA and 5:3 in FTC. These
results not only suggested that follicular neoplasm espe-
cially FTA is much more common in female than male
patients, but also male patients have higher risk than
female patients to have FTC once they have thyroid fol-
licular neoplasm.
In this study, we found that the average age of patients
with FTA was about 8 years younger than those with
FTC (48.2 ± 11.3 vs. 56.7 ± 11.6 years old, P = 0.02,
which was statistical significance). The average age of
FTC patients is similar to a previous published report[1].
Four or more vessels involved by FTC has been pro-
posed to have a worse prognosis[7,11-15]. Dr. Ghossein
also has suggested to avoid the use of the term “mini-
mally invasive” for those aggressive encapsulated follicu-
lar neoplasms with extensive angioinvasion, because the
FTC with extensive vascular invasion implies a higher
risk for recurrence[12]. It was suggested that the number
of foci of vascular invasion should be mentioned in the
pathology reports on FTCs, with a note regarding the
increased risk of recurrence if at least 4 foci of vascular
invasion are observed[12]. In our study, we had 2 cases
with 4 and 5 vessels involved, respectively. Neither of the
two patients show metastasis or local recurrence at 6
years after lobectomy and subtotal thyroidectomy.
Tumor size greater than 4 cm has been shown to have
worse prognosis[12]. In our study, we found that FTCs
were on average significantly larger than FTA (p = 0.003).
In summary, we found that FTC invades venous ves-
sels in the capsule rather than lymphatic vessels, which
correlates with clinical observation that FTC more fre-
quently metastasize via the blood stream to distant
organs rather than regional lymph nodes. We recom-
mended using IHC stain for CD31 rather than CD34
and D2-40 to confirm vascular invasion in difficult cases
and predict distant metastasis and prognosis.
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